BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY

Core Insights - Bio-Techne Corporation and Regulus Therapeutics Inc. announced continued collaboration following positive topline results from Regulus' Phase 1b MAD study of RGLS8429 for treating Autosomal Dominant Polycystic Kidney Disease (ADPKD) [1] - The collaboration began in 2020 to support biomarker analysis for anti-miR-17 therapies targeting ADPKD [1] Company Overview - Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for research and clinical diagnostics, generating over $1.1 billion in net sales in fiscal 2023 [4] - Regulus Therapeutics Inc. focuses on discovering and developing innovative medicines targeting microRNAs, with a strong intellectual property estate in the microRNA field [5] Technical Collaboration - Regulus utilized Bio-Techne's Simple Western platforms and ExosomeDx CLIA laboratory to generate clinical data for RGLS8429, enabling efficient workflows for quantifying therapeutic proteins [2] - High-performance biomarker assays developed by Regulus measure polycystin 1 (PC1) and polycystin 2 (PC2) levels in urine samples, providing key mechanistic and pharmacodynamic information for ADPKD patients [3] Future Outlook - Bio-Techne's President expressed optimism about continuing collaboration with Regulus to advance the study and support other biotech companies in developing innovative therapeutics [4]